Navigating Non-interventional Post-authorization Studies in East Asia: Regulatory Challenges, Opportunities, and...

Area of Science:

• Pharmacoepidemiology
• Regulatory Science
• Pharmacovigilance

Background:

• Post-authorization studies (PAS) are regulatory requirements for pharmaceutical marketing authorization.
• Significant variations in regulatory requirements and operational limitations exist in China, Japan, and South Korea.
• Active surveillance studies, a form of primary data collection, are commonly used in East Asia.

Purpose of the Study:

• To explore regulations and trends of PAS in China, Japan, and South Korea.
• To identify scientific and operational limitations of current PAS practices.
• To propose a decision tool for planning PAS in these regions.

Main Methods:

• Review of pharmacovigilance guidelines and publications on regional regulatory trends.
• Analysis of limitations in traditional active surveillance studies (e.g., absence of comparator, bias, resource intensity).
• Identification of a trend towards hypothesis testing studies using secondary data.

Main Results:

• Traditional active surveillance studies present limitations in characterizing drug safety profiles.
• There is a growing preference for secondary data studies (e.g., electronic databases) over primary data collection.
• Harmonization of regulatory approaches and improved data access are crucial for evidence generation.

Conclusions:

• Current PAS practices in East Asia have significant limitations.
• A shift towards secondary data analysis is a key trend.
• A decision tool is proposed to aid PAS planning, emphasizing harmonized regulations and data access.